Collectively, these studies raise serious safety and efficacy concerns for the use of anti-ACVR1 antibodies as a treatment modality to block ligand-receptor interactions in patients with FOP. The gene discussed is ACVR1; the disease is fibrodysplasia ossificans progressiva.